Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.9493
+0.0993 (11.68%)
At close: May 19, 2025, 4:00 PM
0.9020
-0.0473 (-4.98%)
After-hours: May 19, 2025, 7:49 PM EDT
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,686,361
Market Cap
41.77M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
QNCX News
- 4 days ago - Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 - Seeking Alpha
- 6 days ago - Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - Business Wire
- 19 days ago - Quince Therapeutics to Present at Citizens Life Sciences Conference - Business Wire
- 6 weeks ago - Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - Business Wire
- 2 months ago - Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
- 3 months ago - Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 3 months ago - Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire